Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC). Special Diabetes Program Initiative Renewal

May 2023 Council

Lead Division/Office

DDN, DEM

Point(s) of Contact

Maren Laughlin, Ph.D.; Jose Serrano, M.D., Ph.D.; Aynur Unalp-Arida, M.D., M.Sc., Ph.D.

Executive Summary

Acute pancreatitis (AP) results from acute inflammatory injury of the pancreas, which can be complicated with acute glucose intolerance. Once thought to be a transient effect of the exocrine pancreas, recent clinical studies revealed that 30-40% of patients with AP developed diabetes or impaired glucose tolerance within 3-4 years of even a single, mild episode of AP. The conceptual origin of the T1DAPC, the combined efforts of NIDDK's Divisions of Diabetes, Endocrinology, and Metabolic Diseases and Digestive Diseases and Nutrition led to the issue of RFA-DK-19-022 to fund clinical sites, RFA-DK-19-023 to fund a coordinating center, and RFA-DK-21-501 to provide funding for MRI studies of pancreas architecture and function. The objectives were to form multi-disciplinary teams composed of pancreatologists, endocrinologists, immunologists, and radiologists to conduct a clinical study to investigate the incidence, etiology and pathophysiology of diabetes following AP with a particular emphasis on the auto-immune processes that result in Type 1 diabetes (T1D). As a result, the Diabetes Related to Acute pancreatitis and its Mechanisms (DREAM) study was initiated in 2022. Given the Divisions investments, and the investigators commitment and significant progress, we propose a continuation of the consortium to allow completion of the DREAM Study to accomplish several of the goals stated in the original RFAs.